These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
527 related articles for article (PubMed ID: 22671571)
1. Impact of rituximab on treatment outcomes of patients with diffuse large b-cell lymphoma: a population-based analysis. Lee L; Crump M; Khor S; Hoch JS; Luo J; Bremner K; Krahn M; Hodgson DC Br J Haematol; 2012 Aug; 158(4):481-8. PubMed ID: 22671571 [TBL] [Abstract][Full Text] [Related]
2. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. Coiffier B; Lepage E; Briere J; Herbrecht R; Tilly H; Bouabdallah R; Morel P; Van Den Neste E; Salles G; Gaulard P; Reyes F; Lederlin P; Gisselbrecht C N Engl J Med; 2002 Jan; 346(4):235-42. PubMed ID: 11807147 [TBL] [Abstract][Full Text] [Related]
3. Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma. Stefancikova L; Moulis M; Fabian P; Vasova I; Zedek F; Ravcukova B; Muzik J; Kuglik P; Vranova V; Falkova I; Hrabalkova R; Smardova J Int J Oncol; 2011 Dec; 39(6):1413-20. PubMed ID: 21874232 [TBL] [Abstract][Full Text] [Related]
4. Treatment of gastrointestinal diffuse large B cell lymphoma in China: a 10-year retrospective study of 114 cases. Li X; Shen W; Cao J; Wang J; Chen F; Wang C; Zou S; Shen B; Zhao R; Li J; Shen Z Ann Hematol; 2012 Nov; 91(11):1721-9. PubMed ID: 22733613 [TBL] [Abstract][Full Text] [Related]
5. Strikingly high false positivity of surveillance FDG-PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab era. Avivi I; Zilberlicht A; Dann EJ; Leiba R; Faibish T; Rowe JM; Bar-Shalom R Am J Hematol; 2013 May; 88(5):400-5. PubMed ID: 23423884 [TBL] [Abstract][Full Text] [Related]
6. The comparison between CHOP and R-CHOP in primary gastric diffuse large B cell lymphoma. Sohn BS; Kim SM; Yoon DH; Kim S; Lee DH; Kim JH; Lee SW; Huh J; Suh C Ann Hematol; 2012 Nov; 91(11):1731-9. PubMed ID: 22752193 [TBL] [Abstract][Full Text] [Related]
7. [Evaluation of the impact of R-CHOP chemotherapy on efficacy, safety and prognosis in newly diagnosed diffuse large B-cell lymphoma patients and its prognostic impact: a multicenter retrospective study with long term follow-up]. Cheng ZX; Zou SH; Li F; Li JM; Wang JM; Chen FY; Cao JN; Wang C; Wei Z; Cheng YF Zhonghua Xue Ye Xue Za Zhi; 2012 Apr; 33(4):257-60. PubMed ID: 22781712 [TBL] [Abstract][Full Text] [Related]
8. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in China: a 10-year retrospective follow-up analysis of 437 cases from Shanghai Lymphoma Research Group. Li X; Liu Z; Cao J; Hong X; Wang J; Chen F; Wang C; Zou S; Li J; Shen Z Ann Hematol; 2012 Jun; 91(6):837-45. PubMed ID: 22160255 [TBL] [Abstract][Full Text] [Related]
9. Impact of age group on febrile neutropenia risk assessment and management in patients with diffuse large B-cell lymphoma treated with R-CHOP regimens. Lugtenburg P; Silvestre AS; Rossi FG; Noens L; Krall W; Bendall K; Szabo Z; Jaeger U Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):297-305. PubMed ID: 23040435 [TBL] [Abstract][Full Text] [Related]
10. Improved therapeutic outcomes of DLBCL after introduction of rituximab in Korean patients. Park YH; Lee JJ; Ryu MH; Kim SY; Kim DH; Do YR; Lee KH; Oh SJ; Kim YK; Suh CW; Heo DS; Ryoo BY; Kim JK; Song HS; Lee WS; Kim HJ; Bang YJ; Yang SH; Sohn SK; Kang YK; Ann Hematol; 2006 Apr; 85(4):257-62. PubMed ID: 16416337 [TBL] [Abstract][Full Text] [Related]
11. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. Feugier P; Van Hoof A; Sebban C; Solal-Celigny P; Bouabdallah R; Fermé C; Christian B; Lepage E; Tilly H; Morschhauser F; Gaulard P; Salles G; Bosly A; Gisselbrecht C; Reyes F; Coiffier B J Clin Oncol; 2005 Jun; 23(18):4117-26. PubMed ID: 15867204 [TBL] [Abstract][Full Text] [Related]
12. A success story: how a single targeted-therapy molecule impacted on treatment and outcome of diffuse large B-cell lymphoma. Mian M; Augustin F; Kocher F; Gunsilius E; Willenbacher W; Zabernigg A; Zangerl G; Oexle H; Schreieck S; Schnallinger M; Fiegl M Anticancer Res; 2014 May; 34(5):2559-64. PubMed ID: 24778077 [TBL] [Abstract][Full Text] [Related]
13. Serum interleukin-18 level is associated with the outcome of patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP regimens. Goto N; Tsurumi H; Kasahara S; Kanemura N; Hara T; Yasuda I; Shimizu M; Murakami N; Sawada M; Yamada T; Takemura M; Seishima M; Kito Y; Takami T; Moriwaki H Eur J Haematol; 2011 Sep; 87(3):217-27. PubMed ID: 21575062 [TBL] [Abstract][Full Text] [Related]
14. Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab. Tai WM; Chung J; Tang PL; Koo YX; Hou X; Tay KW; Quek R; Tao M; Lim ST Ann Hematol; 2011 Jul; 90(7):809-18. PubMed ID: 21229246 [TBL] [Abstract][Full Text] [Related]
15. Retrospective analysis of primary gastric diffuse large B cell lymphoma in the rituximab era: a multicenter study of 95 patients in Japan. Tanaka T; Shimada K; Yamamoto K; Hirooka Y; Niwa Y; Sugiura I; Kitamura K; Kosugi H; Kinoshita T; Goto H; Nakamura S Ann Hematol; 2012 Mar; 91(3):383-90. PubMed ID: 21822617 [TBL] [Abstract][Full Text] [Related]
16. Treatment of older patients with mantle-cell lymphoma. Kluin-Nelemans HC; Hoster E; Hermine O; Walewski J; Trneny M; Geisler CH; Stilgenbauer S; Thieblemont C; Vehling-Kaiser U; Doorduijn JK; Coiffier B; Forstpointner R; Tilly H; Kanz L; Feugier P; Szymczyk M; Hallek M; Kremers S; Lepeu G; Sanhes L; Zijlstra JM; Bouabdallah R; Lugtenburg PJ; Macro M; Pfreundschuh M; Procházka V; Di Raimondo F; Ribrag V; Uppenkamp M; André M; Klapper W; Hiddemann W; Unterhalt M; Dreyling MH N Engl J Med; 2012 Aug; 367(6):520-31. PubMed ID: 22873532 [TBL] [Abstract][Full Text] [Related]
17. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. Habermann TM; Weller EA; Morrison VA; Gascoyne RD; Cassileth PA; Cohn JB; Dakhil SR; Woda B; Fisher RI; Peterson BA; Horning SJ J Clin Oncol; 2006 Jul; 24(19):3121-7. PubMed ID: 16754935 [TBL] [Abstract][Full Text] [Related]
18. Impact of central nervous system (CNS) prophylaxis on the incidence and risk factors for CNS relapse in patients with diffuse large B-cell lymphoma treated in the rituximab era: a single centre experience and review of the literature. Guirguis HR; Cheung MC; Mahrous M; Piliotis E; Berinstein N; Imrie KR; Zhang L; Buckstein R Br J Haematol; 2012 Oct; 159(1):39-49. PubMed ID: 22849793 [TBL] [Abstract][Full Text] [Related]
19. High Ki-67 expression in diffuse large B-cell lymphoma patients with non-germinal center subtype indicates limited survival benefit from R-CHOP therapy. Li ZM; Huang JJ; Xia Y; Zhu YJ; Zhao W; Wei WX; Jiang WQ; Lin TY; Huang HQ; Guan ZZ Eur J Haematol; 2012 Jun; 88(6):510-7. PubMed ID: 22413767 [TBL] [Abstract][Full Text] [Related]
20. [Comparison between R-CHOP regimen and CHOP regimen in treating naive diffuse large B-cell lymphoma in China--a multi-center randomized trail]. Lin TY; Zhang HY; Huang Y; Guan ZZ; Shen T; Shi YK; Zhu J; Ke XY; Wang HQ; Shen ZX; Yu SY; Liu T; Shi XL Ai Zheng; 2005 Dec; 24(12):1421-6. PubMed ID: 16351785 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]